Biotech co-founder settles major research misconduct allegations with HHS
In one life, Viravuth Yin is an internationally-recognized expert in regenerative biology who pioneered the use of the zebrafish as a drug screening platform, discovered a potential new regenerative heart drug and spun that discovery into a new biotech startup known as Novo Biosciences, where he now serves as co-founder and CSO.
But in another life, a life that he’s trying to move past with an HHS settlement on Wednesday, Yin is alleged to have committed major research misconduct, including “knowingly, intentionally, and/or recklessly falsifying and/or fabricating data” on three published papers and two manuscripts. Those three published papers, two of which were published in iScience, will now be retracted, at Yin’s request, according to the settlement.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters